
The pharmaceutical giant Roche has in a short time seized large portions of the world's hemophiliac market, a lead that the Swiss company and competitor of Novo Nordisk expects to maintain.
Even if a company like Novo Nordisk should succeed in sending to market another hemophilia drug, which looks better on paper than Roche's Hemlibra, says CEO Bill Anderson at Roche Pharmaceuticals.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app